Pediatrics Certificate

   
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

This activity is intended for pharmacists responsible for the care of pediatric patients, or who have an interest in learning more about pediatric pharmacy practice.

Introduction to Pediatrics
ACPE #: 0204-0000-26-755-H01-P
Application-based
3.5 contact hours 

Learning Objectives:

• Differentiate the assessment of a pediatric patient from an adult patient.
• Design a communication plan for a pediatric patient.
• Recognize normal growth, lab values, and vital signs for a pediatric patient.
• Apply principles of pharmacokinetic changes during growth while assessing medication orders for pediatric patients.
• Calculate creatinine clearance for a pediatric patient.
• Use resources for answering medication questions related to pediatrics, pregnancy, and lactation.
• Calculate a weight-based or body surface area-based dose for a pediatric patient.
• Solve common dosage formulation issues for pediatric patients.
• Discuss pediatric specific concepts and challenges related to sterile and non-sterile compounding.
• Identify appropriate devices and techniques to ensure safe medication administration and adherence in pediatric patients. 

Medication Safety
ACPE #: 0204-0000-26-756-H05-P
Application-based
1 contact hour 

Learning Objectives:

• Differentiate risk factors that lead to adverse drug events in pediatric patients.
• Apply risk mitigation strategies to improve patient safety in pediatric patients.
• Identify methods to optimize healthcare technology for safe care of pediatric patients. 

Fluids, Electrolytes, and Nutrition
ACPE #: 0204-0000-26-757-H01-P
Application-based
4.5 contact hours 

Learning Objectives:

• Describe pediatric intravenous fluids appropriate for a pediatric patient.
• Recognize the signs and symptoms of pediatric dehydration.
• Differentiate characteristics of various peripheral and central venous access devices.
• Compute a pediatric patient’s maintenance intravenous fluid rate and potential fluid deficit.
• Design a fluid replacement regimen for a pediatric dehydration patient.
• Explain why neonates and infants require a specialized amino acid solution when receiving parenteral nutrition.
• Discuss complications and limitations patients may experience with parenteral nutrition.
• Identify monitoring parameters for a pediatric patient receiving parenteral nutrition.
• Recommend an appropriate feeding route and regimen.
• Explain how to administer medications to a patient with an enteral feeding tube. 

Neonatology and Extracorporeal Membrane Oxygenation
ACPE #: 0204-0000-26-758-H01-P
Application-based
2.75 contact hours 

Learning Objectives:

• Summarize physiologic differences in newborns including pharmacokinetic and pharmacodynamic differences.
• Identify standard interventions recommended / required at birth along with the rationale for each.
• Apply strategies utilized in prevention of bronchopulmonary dysplasia.
• Compare treatment options for each of the following: apnea of prematurity, necrotizing enterocolitis, respiratory distress of the newborn, and patent ductus arteriosus.
• Describe unexpected complications encountered in newborns.
• Develop pharmacotherapy recommendations for the management of complications in the newborn.
• Summarize pharmacokinetic and pharmacodynamic changes that occur during extracorporeal membrane oxygenation. 

Pain and Sedation
ACPE #: 0204-0000-26-759-H08-P
Application-based
2 contact hours 

Learning Objectives:

• Select the most appropriate scale to assess pain and sedation when given a neonatal patient case.
• Recommend the most appropriate intervention/agent according to the six-step approach to analgesia in the neonatal patient when given a patient case.
• Compare the short- and long-term effects in preterm neonates with the use of morphine, fentanyl, dexmedetomidine, and midazolam for sedation during mechanical ventilation.
• Compare scales used to assess pain & sedation in critically ill infants and children.
• Select a first-line opioid infusion (i.e., morphine, hydromorphone, fentanyl, remifentanil) for a critically ill child when given a patient case.
• Identify the advantages & disadvantages of the use of midazolam, propofol, and ketamine as an adjunct sedative infusion when given a patient case. 

Congenital Heart Disease and Pulmonary Hypertension
ACPE #: 0204-0000-26-760-H01-P
Application-based
3.5 contact hours 

Learning Objectives:

• Describe the pathophysiology of congenital heart diseases and pulmonary hypertension.
• Identify pharmacokinetic and pharmacodynamic facets of medications used to treat congenital heart diseases and pulmonary hypertension.
• Explain place-in-therapy of medications used to treat congenital heart diseases and pulmonary hypertension.
• Differentiate place-in-therapy of presented medications for patients with congenital heart diseases and pulmonary hypertension.
• Identify the clinical criteria necessary for the diagnosis of Kawasaki disease.
• Determine the appropriate therapeutic interventions for Kawasaki disease based on patient-specific presentation.
• Describe the structured approach for the assessment and treatment of pediatric patients requiring advanced life support.
• Identify the appropriate therapeutic interventions based on patient-specific presentation.
• Provide recommendations for the diagnosis, evaluation, and treatment of hypertension in a pediatric patient.
• List medications used to treat common chronic complications of cystic fibrosis.
• Develop an antibiotic plan for treatment of a cystic fibrosis pulmonary exacerbation in an outpatient and inpatient setting.
• Apply the stepwise approach for chronic asthma management to a patient case.
• Design an acute treatment regimen for an asthma exacerbation.
• Identify cough and cold medications that should be avoided in pediatric patients. 

Infectious Diseases
ACPE #: 0204-0000-26-761-H01-P
Application-based
3.75 contact hours 

Learning Objectives:

• Analyze the impact of the components that comprise an antimicrobial stewardship program.
• Develop an immunization care plan for a hospitalized neonate, child, and adolescent.
• Justify empiric antimicrobial treatment recommendations for sepsis and urinary tract infections.
• Discuss issues in treating pediatric patients presenting with COVID-19.
• Differentiate risk factors, common etiologies, and the clinical presentation of a pediatric patient with acute otitis media, bronchiolitis, influenza, pneumonia, or meningitis.
• Develop a treatment plan for a pediatric patient with acute otitis media, bronchiolitis, influenza, pneumonia, or meningitis.
• Develop an appropriate antimicrobial therapy regimen for common skin / soft tissue and/or bone / joint infections when given a pediatric patient case.
• Compare recommended antimicrobial regimens for Clostridioides difficile infections in pediatric patients to adult patients using the 2017 IDSA and SHEA guidelines for Clostridioides difficile infection in adults and children.
• Develop an antifungal treatment regimen in a critically ill pediatric patient with candidemia.
• Develop an appropriate antifungal treatment regimen in a critically ill pediatric patient with candidemia. 

Neurological / Psychiatric, Gastrointestinal, and Endocrine Disorders
ACPE #: 0204-0000-26-762-H01-P
Application-based
4.75 contact hours 

Learning Objectives:

• Compare drug therapies used for the treatment of common neurologic conditions in pediatric patients, including common epilepsy syndromes.
• Identify first-line medications for the treatment of acute neurologic conditions in children, including status epilepticus.
• Compare drug therapies used for the treatment of common neurologic conditions in pediatric patients, including migraine headaches.
• Identify first-line medications for the treatment of acute neurologic conditions in children, including migraine headaches.
• Compare drug therapies used for the treatment of common neurologic conditions in pediatric patients including cerebral palsy.
• Recommend pharmacotherapy regimens with good patient tolerability to manage symptoms in children with attention-deficit hyperactivity disorder or autism spectrum disorder.
• Apply recommendations for the safe and effective use of antidepressants to manage depression, obsessive compulsive disorder, and PTSD symptoms in children and adolescents.
• Compare the strength of evidence and tolerability of antipsychotics and mood stabilizers for managing bipolar disorder and schizophrenia in children and adolescents.
• Design a treatment regimen for an infant presenting with GERD.
• Calculate the replacement fluid needs for a pediatric patient with acute diarrhea.
• Create a treatment plan for a pediatric patient with functional constipation.
• Design a monitoring plan for agents used in ulcerative colitis and Crohn’s disease in pediatric patients.
• Develop a treatment plan for a child with type 1 or type 2 diabetes mellitus.
• Select appropriate devices for treating and monitoring a child with type 1 diabetes mellitus. 

Pharmacogenomics, Hematology and Oncology Conditions, and Toxicology
ACPE #: 0204-0000-26-763-H01-P
Application-based
3.25 contact hours 

Learning Objectives:

• Describe general principles of pharmacogenomics.
• List currently available clinical pharmacogenomics guidelines that have implications for pediatrics.
• Apply available clinical guidelines to a sample patient case.
• Evaluate chemotherapy regimens used commonly in pediatric oncology for indication, dosing, common toxicities, supportive care, and monitoring parameters.
• Describe the clinical presentation, pharmacotherapeutic plan and common toxicities of a pediatric patient with acute lymphoblastic leukemia.
• Design a maintenance chemotherapy treatment plan for a pediatric patient with acute lymphoblastic leukemia based on pharmacogenomic patient data.
• Apply evidence-based recommendations in the management of patients with sickle cell disease.
• Identify novel therapeutic treatment strategies for patients with sickle cell disease.
• Analyze anticoagulation treatment strategies in the management of pediatric venous thromboembolism.
• Recognize common toxidromes and antidotes.
• Develop treatment regimens for select poisonings.

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

The following persons in control of this activity’s content have relevant financial relationships: 

M. Petrea Cober:

• BBraun/CAPS - Consultant
• Baxter - Consultant
• Fresenius Kabi - Consultant and Speaker 

Kathleen Gura:

• BBraun - Advisory Board
• Baxter - Advisory Board
• Otsuka - Consultant
• Reckitt/Mead Johnson - Advisory Board 

All other persons in control of content do not have any relevant financial relationships with an ineligible company. 

As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity. 

Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity.

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

Important Note – ACPE 60 Day Deadline:

Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. To verify that you have completed the required steps and to ensure your credits have been reported to CPE Monitor, check your NABP profile account to validate that your credits were transferred successfully before the ACPE 60-day deadline. After the 60-day deadline, ASHP will no longer be able to award credit for this activity. 

ASHP PROFESSIONAL CERTIFICATES℠ contain learning activities that are ACPE-accredited knowledge and application-based continuing education. This is not an ACPE Certificate Program. Upon successful completion of the activities, the learner will be able to download an ASHP Professional Certificate.